Cargando…
Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry
Patients with relapsed and/or refractory multiple myeloma (RRMM) generally have limited treatment options and a poor prognosis. Previous trials demonstrated that pomalidomide combined with low-dose dexamethasone (Pd) is effective in these patients with significant responses and improved progression-...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797586/ https://www.ncbi.nlm.nih.gov/pubmed/35106452 http://dx.doi.org/10.1097/HS9.0000000000000683 |
_version_ | 1784641587490324480 |
---|---|
author | Wester, Ruth Dinmohamed, Avinash G. van der Holt, Bronno Zweegman, Sonja Minnema, Monique Croockewit, Sandra Levin, Mark-David Libourel, Eduard de Waal, Esther Sonneveld, Pieter Cornelissen, Jan Blijlevens, Nicole Broijl, Annemiek |
author_facet | Wester, Ruth Dinmohamed, Avinash G. van der Holt, Bronno Zweegman, Sonja Minnema, Monique Croockewit, Sandra Levin, Mark-David Libourel, Eduard de Waal, Esther Sonneveld, Pieter Cornelissen, Jan Blijlevens, Nicole Broijl, Annemiek |
author_sort | Wester, Ruth |
collection | PubMed |
description | Patients with relapsed and/or refractory multiple myeloma (RRMM) generally have limited treatment options and a poor prognosis. Previous trials demonstrated that pomalidomide combined with low-dose dexamethasone (Pd) is effective in these patients with significant responses and improved progression-free survival (PFS). Pd has been approved in RRMM patients who received ≥2 prior lines of therapy. Here, we present the results of a population-based study of patients with RRMM treated with Pd in The Netherlands from time of pomalidomide approval. Using the nationwide Netherlands Cancer Registry, data from all nontrial patients with RRMM treated with Pd were collected. Data were analyzed of response, PFS, and overall survival (OS). A total of 237 patients were included in this analysis. Previous treatment consisted of a proteasome inhibitor in 227 patients (96%) and/or an immune-modulating agent in 235 patients (99%). One hundred forty patients (59%) were refractory to an immune-modulating agent in their last line of therapy. Median time from diagnosis to treatment with Pd was 4.9 years (interquartile range, 2.7–7.9), and the median number of prior treatments was 4 (interquartile range, 3–5). Median PFS and OS for all patients were 3.6 months (95% confidence interval [CI], 3.1–3.8) and 7.7 months (95% CI, 5.7–9.7), respectively. For patients achieving ≥PR, median PFS and OS were 10.6 months (95% CI, 8.3–12.9) and 16.3 months (95% CI, 13.6–23.2), respectively. This nationwide, population-based registry study confirms data shown in pivotal clinical trials on Pd. PFS in this analysis is comparable to PFS observed in those clinical trials. |
format | Online Article Text |
id | pubmed-8797586 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-87975862022-01-31 Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry Wester, Ruth Dinmohamed, Avinash G. van der Holt, Bronno Zweegman, Sonja Minnema, Monique Croockewit, Sandra Levin, Mark-David Libourel, Eduard de Waal, Esther Sonneveld, Pieter Cornelissen, Jan Blijlevens, Nicole Broijl, Annemiek Hemasphere Article Patients with relapsed and/or refractory multiple myeloma (RRMM) generally have limited treatment options and a poor prognosis. Previous trials demonstrated that pomalidomide combined with low-dose dexamethasone (Pd) is effective in these patients with significant responses and improved progression-free survival (PFS). Pd has been approved in RRMM patients who received ≥2 prior lines of therapy. Here, we present the results of a population-based study of patients with RRMM treated with Pd in The Netherlands from time of pomalidomide approval. Using the nationwide Netherlands Cancer Registry, data from all nontrial patients with RRMM treated with Pd were collected. Data were analyzed of response, PFS, and overall survival (OS). A total of 237 patients were included in this analysis. Previous treatment consisted of a proteasome inhibitor in 227 patients (96%) and/or an immune-modulating agent in 235 patients (99%). One hundred forty patients (59%) were refractory to an immune-modulating agent in their last line of therapy. Median time from diagnosis to treatment with Pd was 4.9 years (interquartile range, 2.7–7.9), and the median number of prior treatments was 4 (interquartile range, 3–5). Median PFS and OS for all patients were 3.6 months (95% confidence interval [CI], 3.1–3.8) and 7.7 months (95% CI, 5.7–9.7), respectively. For patients achieving ≥PR, median PFS and OS were 10.6 months (95% CI, 8.3–12.9) and 16.3 months (95% CI, 13.6–23.2), respectively. This nationwide, population-based registry study confirms data shown in pivotal clinical trials on Pd. PFS in this analysis is comparable to PFS observed in those clinical trials. Lippincott Williams & Wilkins 2022-01-27 /pmc/articles/PMC8797586/ /pubmed/35106452 http://dx.doi.org/10.1097/HS9.0000000000000683 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Article Wester, Ruth Dinmohamed, Avinash G. van der Holt, Bronno Zweegman, Sonja Minnema, Monique Croockewit, Sandra Levin, Mark-David Libourel, Eduard de Waal, Esther Sonneveld, Pieter Cornelissen, Jan Blijlevens, Nicole Broijl, Annemiek Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry |
title | Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry |
title_full | Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry |
title_fullStr | Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry |
title_full_unstemmed | Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry |
title_short | Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry |
title_sort | pomalidomide in patients with relapsed and/or refractory multiple myeloma: a prospective study within the nationwide netherlands cancer registry |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797586/ https://www.ncbi.nlm.nih.gov/pubmed/35106452 http://dx.doi.org/10.1097/HS9.0000000000000683 |
work_keys_str_mv | AT westerruth pomalidomideinpatientswithrelapsedandorrefractorymultiplemyelomaaprospectivestudywithinthenationwidenetherlandscancerregistry AT dinmohamedavinashg pomalidomideinpatientswithrelapsedandorrefractorymultiplemyelomaaprospectivestudywithinthenationwidenetherlandscancerregistry AT vanderholtbronno pomalidomideinpatientswithrelapsedandorrefractorymultiplemyelomaaprospectivestudywithinthenationwidenetherlandscancerregistry AT zweegmansonja pomalidomideinpatientswithrelapsedandorrefractorymultiplemyelomaaprospectivestudywithinthenationwidenetherlandscancerregistry AT minnemamonique pomalidomideinpatientswithrelapsedandorrefractorymultiplemyelomaaprospectivestudywithinthenationwidenetherlandscancerregistry AT croockewitsandra pomalidomideinpatientswithrelapsedandorrefractorymultiplemyelomaaprospectivestudywithinthenationwidenetherlandscancerregistry AT levinmarkdavid pomalidomideinpatientswithrelapsedandorrefractorymultiplemyelomaaprospectivestudywithinthenationwidenetherlandscancerregistry AT liboureleduard pomalidomideinpatientswithrelapsedandorrefractorymultiplemyelomaaprospectivestudywithinthenationwidenetherlandscancerregistry AT dewaalesther pomalidomideinpatientswithrelapsedandorrefractorymultiplemyelomaaprospectivestudywithinthenationwidenetherlandscancerregistry AT sonneveldpieter pomalidomideinpatientswithrelapsedandorrefractorymultiplemyelomaaprospectivestudywithinthenationwidenetherlandscancerregistry AT cornelissenjan pomalidomideinpatientswithrelapsedandorrefractorymultiplemyelomaaprospectivestudywithinthenationwidenetherlandscancerregistry AT blijlevensnicole pomalidomideinpatientswithrelapsedandorrefractorymultiplemyelomaaprospectivestudywithinthenationwidenetherlandscancerregistry AT broijlannemiek pomalidomideinpatientswithrelapsedandorrefractorymultiplemyelomaaprospectivestudywithinthenationwidenetherlandscancerregistry |